Long-acting HIV treatment: how well it works in real life

This study is tracking people with HIV in Switzerland who are starting a new long-acting injectable treatment called cabotegravir plus rilpivirine (CAB+RPV LA). Researchers want to understand how well this medication works in everyday clinical practice, how consistently people use it, and what factors might affect whether the treatment succeeds or fails. The study will compare outcomes for people on this new medication with those staying on traditional daily oral HIV medications.

While this medication has shown promise in clinical trials, researchers want to understand how it performs in real-world settings with diverse patients and different life circumstances. This will help doctors know when this treatment is right for patients and identify which people might need extra support to succeed with it.